BioPharma Drive: Drug Pricing

APRIL 25, 2025

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.

Marketing 263

Marketing Drugs 263

BioPharma Drive: Drug Pricing

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 251

Marketing Drugs 251

Drug Channels

NOVEMBER 15, 2024

The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. TThey argue that unified datasets and the addition of AI-driven analytics tools can improve decision making throughout a drug’s life cycle. Read on for their insights.

Marketing 98

Marketing International Drugs 98

Covalent Modifiers

MAY 28, 2025

However, the inherent targeted covalent inhibitor (TCI) adverse off-target reactivity risk requires a mitigation strategy early during drug discovery. Drug induced liver injury was assessed in primary human hepatocyte spheroids. The mitigation strategy was applied to compound 35, a potent irreversible inhibitor to KRASG12C.

Drugs 130

Drugs Treatment Research Marketing 130

BioPharma Drive: Drug Pricing

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 318

Drugs Marketing 318

BioPharma Drive: Drug Pricing

NOVEMBER 14, 2024

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

Regulations 297

Regulations Drugs Marketing 297

Drugs.com

FEBRUARY 5, 2025

5, 2025 -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.A new study found that a drug in the same class called exenatide, marketed as Byetta, had no effect on slowing the. WEDNESDAY, Feb.

Drugs 276

Drugs Disease Marketing 276

Drug Patent Watch

APRIL 10, 2025

"Just spent the morning digging into the world of pharmaceuticals and I'm blown away by the complexities of drafting effective drug patent applications. The team at Drug Patent Watch has done an incredible job of breaking down the key considerations for turning scientific discoveries into market power.

Science 71

Science Marketing Drugs Pharmaceuticals 71

BioPharma Drive: Drug Pricing

JULY 16, 2024

The well-funded startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.

Drugs 275

Drugs Marketing 275

Drug Patent Watch

FEBRUARY 27, 2025

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. But what can you do to protect your drug patent in global markets? Read the full article here: [link]

Marketing 52

Marketing Drugs Regulations Pharmaceutical Companies 52

BioPharma Drive: Drug Pricing

NOVEMBER 27, 2023

drugmaker withdrew the multiple myeloma drug from the U.S. market because of negative data, new study results might crack open the door to a relaunch. One year after the U.K.

Trials 275

Trials Drugs Marketing 275

BioPharma Drive: Drug Pricing

MAY 3, 2024

The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.

Drugs 279

Drugs Marketing 279

Drugs.com

JANUARY 17, 2025

Food and Drug Administration has authorized the marketing of 20 ZYN nicotine pouch products. FRIDAY, Jan. 17, 2025 -- Following an extensive scientific review, the U.S. Nicotine pouches -- small synthetic fiber pouches containing nicotine -- are.

FDA Approval 130

FDA Approval Marketing FDA Production 130

BioPharma Drive: Drug Pricing

MARCH 26, 2025

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

FDA 318

FDA Marketing Drugs 318

Chemical Biology and Drug Design

MARCH 14, 2025

Fragment-based drug discovery (FBDD) was applied to cytochrome P450 3A4 reconstituted in Nanodiscs (NDs) with various lipid compositions. The choice of ND lipid influenced drug membrane interactions and fragment hit rates, demonstrating the critical role of the membrane environment in fragment screening for membrane proteins.

Fragment Screening 100

Fragment Screening Pharmacokinetics Drugs Marketing 100

Nvidia Developer: Drug Discovery

OCTOBER 30, 2024

The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. Traditional.

Drugs 87

Drugs Treatment Disease Research 87

Drug Patent Watch

SEPTEMBER 26, 2024

The generic drug market is a complex and dynamic environment where multiple factors influence the availability, quality, and pricing of generic drugs. This article will discuss the key strategies and… Source

Marketing 103

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 103

Drug Patent Watch

SEPTEMBER 30, 2024

Patent expirations have a significant impact on the pharmaceutical industry, particularly on the generic drug market. When a drug’s patent expires, other manufacturers can produce and market generic versions of the drug, leading to increased competition and lower prices.

Marketing 103

Marketing Drugs Pharmaceuticals 103

Drug Patent Watch

OCTOBER 10, 2024

China has emerged as a significant player in the global generic drug active pharmaceutical ingredient (API) market. This article will delve into the role of China in the global generic drug API market, exploring its market share… Source

Marketing 109

Marketing Pharmaceutical Companies Drugs Pharmaceuticals 109

Drug Patent Watch

DECEMBER 10, 2024

India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. This article delves into India’s growing importance in generic drug API manufacturing, highlighting the key factors contributing to its success and the challenges it faces.

Government 88

Government Drugs Pharmacy Pharmaceuticals 88

Drug Patent Watch

OCTOBER 21, 2024

The filing of drug patents in emerging markets is a critical aspect of this protection, as it ensures that companies can recoup their investments and… Source The pharmaceutical industry is a significant contributor to the global economy, with a substantial portion of its production costs incurred during the development stage.

Marketing 100

Marketing Drugs Pharmaceuticals Production 100

BioPharma Drive: Drug Pricing

AUGUST 24, 2023

The subsidiary, called Cordavis, will work directly with manufacturers to market or co-produce low-cost biologic drugs, starting with Novartis’ Humira copy.

Biosimilars 243

Biosimilars Drugs Marketing 243

Drug Patent Watch

DECEMBER 10, 2024

This shift has led to the emergence of integrated contract development and manufacturing organizations (CDMOs), which provide end-to-end support for drug developers. In this article, we will delve into the benefits of working with integrated CDMO services and explore how they can streamline the drug development and manufacturing process.

Drug Development 81

Drug Development Compliance Pharmaceutical Companies Drugs 81

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Licensing 81

Licensing Licensing Drugs Biosimilars 81

BioPharma Drive: Drug Pricing

MARCH 8, 2024

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

Marketing 340

Marketing Drugs 340

PPD

NOVEMBER 11, 2024

It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drug development. As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients.

Drug Development 97

Drug Development Clinical Trials Drugs Small Molecule 97

BioPharma Drive: Drug Pricing

APRIL 4, 2024

In the wake of a major trial failure, the company is withdrawing Relyvrio and cutting costs with a restructuring that involves laying off 70% of its employees.

Marketing 174

Marketing Trials Drugs 174

Drug Target Review

APRIL 30, 2025

In the rapidly evolving field of cell and gene therapy (CGT), the ability to manage complex biological data, optimise manufacturing processes, and accelerate drug discovery is crucial. Faster time-to-market and reduced costs. Zylberberg has built an impressive career at the intersection of science, technology, and business. The result?

Therapies 90

Therapies Drugs Clinical Trials Trials 90

BioPharma Drive: Drug Pricing

DECEMBER 4, 2024

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.

Drug Trials 303

Drug Trials Trials Treatment Marketing 303

Drug Patent Watch

JANUARY 30, 2025

Maximizing Patent Protection: Strategies for Pharmaceutical Marketers As a pharmaceutical marketer, you know how crucial it is to protect your patented drug's market share. This exclusivity is a result of the patent protection granted to the drug's developer. Read the full article here: [link]

Marketing 52

Marketing Drugs Production Pharmaceuticals 52

BioPharma Drive: Drug Pricing

NOVEMBER 22, 2024

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market that investors have been skeptical BridgeBio can win.

FDA 297

FDA Marketing Drugs 297

BioPharma Drive: Drug Pricing

APRIL 7, 2025

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically driven forms of excess weight.

Marketing 140

Marketing Drugs 140

BioPharma Drive: Drug Pricing

JULY 9, 2024

On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report faults PBMs for profiting at the expense of patients and independent pharmacists.

Marketing 140

Marketing Regulations Drugs 140

Drug Patent Watch

SEPTEMBER 23, 2024

The generic drug market has experienced significant growth over the past few decades, driven by the expiration of patents on branded drugs and the increasing demand for affordable healthcare solutions. However, the industry faces several challenges, including commoditization, regulatory hurdles, and intense competition.

Marketing 94

Marketing Drugs 94

Drug Patent Watch

DECEMBER 9, 2024

This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. But what exactly is pharmacognosy, and how does it relate to the complex world of drug patents? This approach has led to the discovery of numerous potential drug candidates. What is a Drug Patent?

Drugs 88

Drugs Drug Development Pharmaceuticals Production 88

Drug Patent Watch

JULY 25, 2024

The generic drug market has been significantly impacted by the COVID-19 pandemic, with both challenges and opportunities arising from the crisis. As the world continues to recover…

Marketing 98

Marketing Drugs 98

BioPharma Drive: Drug Pricing

MAY 13, 2024

Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.

Therapies 322

Therapies Marketing Drugs 322